💉 GLP-1 weight-loss drugs may not cause as much muscle loss as many feared.
A new systematic review analyzed 36 studies on GLP-1 receptor agonists and dual GLP-1/GIP drugs in adults with overweight or obesity, with or without type 2 diabetes.
The overall pattern was reassuring: most of the weight lost came from fat, including visceral fat around the organs. Lean body mass did decline in some people, but the loss was generally modest compared with the reduction in fat mass.
That does not mean muscle loss is impossible or unimportant. Lean mass can include muscle, water, organs, and other tissues, so body-composition results need careful interpretation.
The practical message is balance: GLP-1 drugs may support “higher-quality” weight loss, but protein intake, resistance training, and medical supervision still matter for protecting strength and long-term health.
📃 RESEARCH PAPER
📌 Sawicka-Gutaj et al., “GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis”, International Journal of Obesity (2026)
